Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/20381
Title
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
Author(s)
Martinez-Lopez, J | Sanchez-Vega, B | Barrio, S | Cuenca, I | Ruiz-Heredia, Y | Alonso, R | Rapado, I | Marin, C | Cedena, M-T | Paiva, B | Puig, N | Mateos, M-V | Ayala, R | Hernandez, M-T | Jimenez, C | Rosinol, L | Martinez, R | Teruel, Ana Isabel | Gutierrez, N | Martin-Ramos, Maria-Luisa | Oriol, A | Bargay Lleonart, Joan | Blade, J | San-Miguel, J | Garcia-Sanz, R | Lahuerta, J-J
Date issued
2017-06
Citation
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.
Language
Inglés
Document type
letter to the editor
MESH
Aged | Male | Monitoring, Physiologic | Multiple Myeloma | Neoplasm, Residual | Female | High-Throughput Nucleotide Sequencing | Humans | Survival Analysis | Antineoplastic Combined Chemotherapy Protocols
DECS
Humanos | Protocolos de Quimioterapia Combinada Antineoplásica | Análisis de Supervivencia | Anciano | Monitoreo Fisiológico | Mieloma Múltiple | Femenino | Secuenciación de Nucleótidos de Alto Rendimiento | Neoplasia Residual | Masculino
Online version
DOI
Collections
Full text access